Cancer Care Ontario | Cancer Care Ontario

zanubrutinib - For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; and for the treatment of adult patients with previously untreated CLL.

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

zanubrutinib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Mar 2024

Drug

selinexor

Other Name(s): Xpovio®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Mar 2024

Guidelines and Advice

Fear of Cancer Recurrence Guideline

Status: Current
ID: GL 19-7

Mar 2024

Guidelines and Advice

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Status: Current
ID: C50-CIDAP-1

Mar 2024

Guidelines and Advice

Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer

Status: Current
ID: GL 1-14
Version: 3

Oct 2019

Guidelines and Advice

Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario

Status: Current
ID: GL 5-3ORG
Version: 2

Apr 2019

Guidelines and Advice

Management of Ductal Carcinoma in Situ of the Breast

Status: Current
ID: GL1-10
Version: 4

Mar 2024

Guidelines and Advice

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline

Status: Current
ID: GL 6-A-2023-1
Version: 2

Mar 2019

DARODOCE

isatuximab

CARFDEXASELI

ZANU

selinexor

Fear of Cancer Recurrence Guideline

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer

Organizational Guidance for the Care of Patients with Head and Neck Cancer in Ontario

Management of Ductal Carcinoma in Situ of the Breast

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline

Pages